Present various platform updates over the next several quarters, including liver NHP data, at scientific conferences, as well as research related to ongoing discovery efforts and pipeline programs. Continue to execute on existing partnership with Eli Lilly. ProQR may selectively form new partnerships, which could include multi-target discovery alliances, similar to the Company’s partnership with Lilly, or product alliances on specific programs. ProQR is on track to advance AX-0810 targeting NTCP and AX-1412 targeting B4GALT1 into clinical development in late 2024/early 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRQR:
- ProQR Announces Second Quarter 2023 Operating and Financial Results
- ProQR Therapeutics to divest sepofarsen, ultevursen assets to Laboratoires Thea
- ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
- ProQR Therapeutics presents data on Axiomer RNA Editing technology
- ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit